ABCM - Abcam plc
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United Kingdom
Type: Equity
ABCM price evolution
ABCM
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $79 | $79 | $89 | $89 |
| Short term investments | ||||
| Net receivables | $108.6 | $108.6 | $90.3 | $90.3 |
| Inventory | $66.3 | $66.3 | $68 | $68 |
| Total current assets | $255.8 | $255.8 | $255.4 | $255.4 |
| Long term investments | $3.5 | $3.5 | $3.2 | $3.2 |
| Property, plant & equipment | $157.5 | $157.5 | $159.7 | $159.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1027.1 | $1027.1 | $1056.6 | $1056.6 |
| Current liabilities | ||||
| Accounts payable | $61.4 | $61.4 | $15.8 | $15.8 |
| Deferred revenue | ||||
| Short long term debt | $127.5 | $127.5 | $128.1 | $128.1 |
| Total current liabilities | $188.9 | $188.9 | $201.8 | $201.8 |
| Long term debt | $89.5 | $89.5 | $95.8 | $95.8 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $307.9 | $307.9 | $329.7 | $329.7 |
| Shareholders' equity | ||||
| Retained earnings | $326.4 | $326.4 | $300.7 | $300.7 |
| Other shareholder equity | $124.6 | $124.6 | $158.2 | $158.2 |
| Total shareholder equity | $719.2 | $719.2 | $726.9 | $726.9 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 30 Jun 2020 | 30 Jun 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $89 | $95.1 | $187.3 | $87.1 |
| Short term investments | ||||
| Net receivables | $90.3 | $52.6 | $46.1 | $43.4 |
| Inventory | $68 | $58.2 | $40.7 | $36 |
| Total current assets | $255.4 | $211.5 | $278.8 | $171.8 |
| Long term investments | $3.2 | $3.5 | $7 | $0.8 |
| Property, plant & equipment | $159.7 | $161.7 | $164.7 | $37.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1056.6 | $986.1 | $811.4 | $446.7 |
| Current liabilities | ||||
| Accounts payable | $15.8 | $12.9 | $9.4 | $7 |
| Deferred revenue | ||||
| Short long term debt | $128.1 | $128.4 | $113.7 | |
| Total current liabilities | $201.8 | $187.2 | $159.6 | $45.3 |
| Long term debt | $95.8 | $101.3 | $120.5 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $329.7 | $330 | $308.8 | $61.9 |
| Shareholders' equity | ||||
| Retained earnings | $300.7 | $358.2 | $324.3 | $328.2 |
| Other shareholder equity | $158.2 | $31.3 | $42.2 | $32 |
| Total shareholder equity | $726.9 | $656.1 | $502.6 | $384.8 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $101.6 | $101.6 | $88.25 | $88.25 |
| Cost of revenue | $24.15 | $24.15 | $21.65 | $21.65 |
| Gross Profit | $77.45 | $77.45 | $66.6 | $66.6 |
| Operating activities | ||||
| Research & development | $9.8 | $9.8 | $8 | $8 |
| Selling, general & administrative | $49.05 | $49.05 | $40.7 | $40.7 |
| Total operating expenses | $83 | $83 | $70.35 | $70.35 |
| Operating income | $18.6 | $18.6 | $17.9 | $17.9 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $3.3 | $3.3 | -$4.35 | -$4.35 |
| Interest expense | -$2.6 | -$2.6 | -$1.95 | -$1.95 |
| Net income | ||||
| Net income | $8.4 | $8.4 | -$7.15 | -$7.15 |
| Income (for common shares) | $8.4 | $8.4 | -$7.15 | -$7.15 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 30 Jun 2020 | 30 Jun 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $361.7 | $462.9 | $260 | $259.9 |
| Cost of revenue | $88.5 | $133.7 | $79.8 | $76.7 |
| Gross Profit | $273.2 | $329.2 | $180.2 | $183.2 |
| Operating activities | ||||
| Research & development | $35.1 | $30.4 | $17.4 | $10.7 |
| Selling, general & administrative | $184.3 | $235.4 | $118.3 | $88.9 |
| Total operating expenses | $307.9 | $438.5 | $249.5 | $203.8 |
| Operating income | $53.8 | $24.4 | $10.5 | $56.1 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$7.1 | $3.1 | -$4.1 | $11.2 |
| Interest expense | -$5.9 | |||
| Net income | ||||
| Net income | -$8.5 | $17.2 | $12.5 | $45 |
| Income (for common shares) | -$8.5 | $17.2 | $12.5 | $45 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | $8.4 | $8.4 | -$7.15 | -$7.15 |
| Operating activities | ||||
| Depreciation | $6.15 | $6.15 | $9.2 | $9.2 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $13.65 | $13.65 | -$0.55 | -$0.55 |
| Investing activities | ||||
| Capital expenditures | -$4.85 | -$4.85 | -$6.15 | -$6.15 |
| Investments | ||||
| Total cash flows from investing | -$10.5 | -$10.5 | -$5.25 | -$5.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.15 | $0.15 | $0.25 | $0.25 |
| Net borrowings | -$2.7 | -$2.7 | -$2.8 | -$2.8 |
| Total cash flows from financing | -$5.9 | -$5.9 | -$4.1 | -$4.1 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5 | -$5 | -$10.3 | -$10.3 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 30 Jun 2020 | 30 Jun 2019 |
|---|---|---|---|---|
| Net income | -$8.5 | $24.4 | $10.5 | $56.1 |
| Operating activities | ||||
| Depreciation | $43.8 | $28.2 | $14 | $4.8 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $28.7 | $96.2 | $63 | $70.2 |
| Investing activities | ||||
| Capital expenditures | -$16.8 | -$84.3 | -$35.7 | -$40.4 |
| Investments | ||||
| Total cash flows from investing | -$24.4 | -$313.7 | -$148.1 | -$49.9 |
| Financing activities | ||||
| Dividends paid | -$25 | -$24.9 | ||
| Sale and purchase of stock | $0.9 | $130.1 | $111.1 | $1.2 |
| Net borrowings | -$11.3 | $0.4 | $100.2 | |
| Total cash flows from financing | -$15.5 | $126.4 | $184.6 | -$24.7 |
| Effect of exchange rate | -$1.1 | $0.7 | $1.3 | |
| Change in cash and equivalents | -$6.1 | -$92.2 | $100.2 | -$3.1 |
News
|
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
Zacks via Yahoo Finance
12 Apr 2024
|
|
Druckenmiller, Soros Cut Stakes in Nvidia After Share Surge
Bloomberg via Yahoo Finance
15 Nov 2023
|
|
George Soros' Major Moves: Spotlight on iShares iBoxx USD Investment Grade Corporate Bond ETF
GuruFocus.com via Yahoo Finance
15 Nov 2023
|
|
Here’s Headwaters Capital’s Perspective on Abcam plc (ABCM) Acquisition
Insider Monkey via Yahoo Finance
15 Nov 2023
|
|
Meta Platforms Inc Takes a Hit in Jeremy Grantham's Latest Portfolio Adjustments
GuruFocus.com via Yahoo Finance
13 Nov 2023
|
|
Here’s Why Baron Discovery Fund Sold Abcam plc (ABCM)
Insider Monkey via Yahoo Finance
9 Nov 2023
|
|
Here’s Why Abcam plc (ABCM) Rose in Q2
Insider Monkey via Yahoo Finance
22 Sep 2023
|
|
FLGB ETF: British Blue Chips Look A Fair Deal
Seeking Alpha
19 Sep 2023
|
|
The 7 Most Undervalued Safe Stocks to Buy in September 2023
InvestorPlace
14 Sep 2023
|
|
The 3 Best Pharma Stocks to Buy Now: September 2023
InvestorPlace
8 Sep 2023
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $379.70M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $2.50M |
| Revenue Q/Q | 9.72% |
| Revenue Y/Y | -24.15% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 0.24% |
| ROE | 0.35% |
| Debt/Equity | 0.45 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.35 |
| Quick ratio | 1.00 |